Dilafor, Lee's Pharmaceutical deal

Dilafor granted Lee's Pharmaceutical exclusive development and commercialization rights in China, including Hong Kong and Macau, and Taiwan to tafoxiparin for obstetrical and gynecological indications. Initial development will focus on reducing labor times in patients who do not start labor spontaneously and are induced into labor. Under the deal, Dilafor will receive an undisclosed upfront payment and be eligible for development and sales milestones and royalties...